BACKGROUND: RNA interference (RNAi) is a powerful tool for suppressing gene function. The tetracycline (tet)-regulated expression system has recently been adapted to allow inducible RNAi in mice, however its efficiency in a particular cell type in vivo depends on a transgenic tet transactivator expression pattern and is often highly variable. OBJECTIVE: We aimed to establish a transgenic strategy that allows efficient and inducible gene knockdown in particular hematopoietic lineages in mice. METHODS AND RESULTS: Using a tet-regulated reporter gene strategy, we found that transgenic mice expressing the rtTA (tet-on) transactivator under control of the cytomegalovirus (CMV) promoter (CMV-rtTA mice) display inducible reporter gene expression with unusual and near-complete efficiency in megakaryocytes and platelets. To test whether the CMV-rtTA transgene can drive inducible and efficient gene knockdown within this lineage, we generated a novel mouse strain harboring a tet-regulated short hairpin RNA (shRNA) targeting Bcl-x(L) , a pro-survival Bcl-2 family member known to be essential for maintaining platelet survival. Doxycycline treatment of adult mice carrying both transgenes induces shRNA expression, depletes Bcl-x(L) in megakaryocytes and triggers severe thrombocytopenia, whereas doxycycline withdrawal shuts off shRNA expression, normalizes Bcl-x(L) levels and restores platelet numbers. These effects are akin to those observed with drugs that target Bcl-x(L) , clearly demonstrating that this transgenic system allows efficient and inducible inhibition of genes in megakaryocytes and platelets. CONCLUSIONS: We have established a novel transgenic strategy for inducible gene knockdown in megakaryocytes and platelets that will be useful for characterizing genes involved in platelet production and function in adult mice.
BACKGROUND: RNA interference (RNAi) is a powerful tool for suppressing gene function. The tetracycline (tet)-regulated expression system has recently been adapted to allow inducible RNAi in mice, however its efficiency in a particular cell type in vivo depends on a transgenic tet transactivator expression pattern and is often highly variable. OBJECTIVE: We aimed to establish a transgenic strategy that allows efficient and inducible gene knockdown in particular hematopoietic lineages in mice. METHODS AND RESULTS: Using a tet-regulated reporter gene strategy, we found that transgenic mice expressing the rtTA (tet-on) transactivator under control of the cytomegalovirus (CMV) promoter (CMV-rtTA mice) display inducible reporter gene expression with unusual and near-complete efficiency in megakaryocytes and platelets. To test whether the CMV-rtTA transgene can drive inducible and efficient gene knockdown within this lineage, we generated a novel mouse strain harboring a tet-regulated short hairpin RNA (shRNA) targeting Bcl-x(L) , a pro-survival Bcl-2 family member known to be essential for maintaining platelet survival. Doxycycline treatment of adult mice carrying both transgenes induces shRNA expression, depletes Bcl-x(L) in megakaryocytes and triggers severe thrombocytopenia, whereas doxycycline withdrawal shuts off shRNA expression, normalizes Bcl-x(L) levels and restores platelet numbers. These effects are akin to those observed with drugs that target Bcl-x(L) , clearly demonstrating that this transgenic system allows efficient and inducible inhibition of genes in megakaryocytes and platelets. CONCLUSIONS: We have established a novel transgenic strategy for inducible gene knockdown in megakaryocytes and platelets that will be useful for characterizing genes involved in platelet production and function in adult mice.
Authors: V Baccini; L Roy; N Vitrat; H Chagraoui; S Sabri; J P Le Couedic; N Debili; F Wendling; W Vainchenker Journal: Blood Date: 2001-12-01 Impact factor: 22.113
Authors: Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg Journal: Nature Date: 2005-05-15 Impact factor: 49.962
Authors: Ross A Dickins; Katherine McJunkin; Eva Hernando; Prem K Premsrirut; Valery Krizhanovsky; Darren J Burgess; Sang Yong Kim; Carlos Cordon-Cardo; Lars Zender; Gregory J Hannon; Scott W Lowe Journal: Nat Genet Date: 2007-06-17 Impact factor: 38.330
Authors: J L Clements; J R Lee; B Gross; B Yang; J D Olson; A Sandra; S P Watson; S R Lentz; G A Koretzky Journal: J Clin Invest Date: 1999-01 Impact factor: 14.808
Authors: Elena Diaz-Rodríguez; Rocio Sotillo; Juan-Manuel Schvartzman; Robert Benezra Journal: Proc Natl Acad Sci U S A Date: 2008-10-21 Impact factor: 11.205
Authors: Brian G Petrich; Patrizia Marchese; Zaverio M Ruggeri; Saskia Spiess; Rachel A M Weichert; Feng Ye; Ralph Tiedt; Radek C Skoda; Susan J Monkley; David R Critchley; Mark H Ginsberg Journal: J Exp Med Date: 2007-12-17 Impact factor: 14.307
Authors: Jessica K Mountford; Claire Petitjean; Harun W Kusuma Putra; Jonathan A McCafferty; Natasha M Setiabakti; Hannah Lee; Lotte L Tønnesen; James D McFadyen; Simone M Schoenwaelder; Anita Eckly; Christian Gachet; Sarah Ellis; Anne K Voss; Ross A Dickins; Justin R Hamilton; Shaun P Jackson Journal: Nat Commun Date: 2015-03-17 Impact factor: 14.919
Authors: Eleonora Ottina; Victor Peperzak; Katia Schoeler; Emma Carrington; Roswitha Sgonc; Marc Pellegrini; Simon Preston; Marco J Herold; Andreas Strasser; Andreas Villunger Journal: Nat Commun Date: 2017-10-18 Impact factor: 14.919
Authors: Megumi Takiguchi; Lukas E Dow; Julia E Prier; Catherine L Carmichael; Benjamin T Kile; Stephen J Turner; Scott W Lowe; David C S Huang; Ross A Dickins Journal: PLoS One Date: 2013-01-11 Impact factor: 3.240